List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5325956/publications.pdf Version: 2024-02-01



HEE LUNC KIM

#	Article	IF	CITATIONS
1	Spinal Versus General Anesthesia for Cesarean Delivery in Pregnant Women With Moyamoya Disease: A Retrospective Observational Study. Anesthesia and Analgesia, 2022, Publish Ahead of Print, .	2.2	1
2	Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer. Oncology Reports, 2022, 47, .	2.6	8
3	Optimal location for continuous catheter analgesia among the femoral triangle, proximal, or distal adductor canal after total knee arthroplasty: a randomized double-blind controlled trial. Regional Anesthesia and Pain Medicine, 2022, 47, 353-358.	2.3	6
4	Management of pulmonary aspiration due to undiagnosed achalasia during induction of general anesthesia - A case report Anesthesia and Pain Medicine, 2022, 17, 239-244.	1.4	3
5	Combination of LMT-28 and Metformin Improves Beneficial Anti-Inflammatory Effect in Collagen-Induced Arthritis. Pharmacology, 2021, 106, 53-59.	2.2	10
6	Bazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer. International Journal of Molecular Sciences, 2021, 22, 8693.	4.1	11
7	LncRNA <i>SRA</i> mediates cell migration, invasion, and progression of ovarian cancer via NOTCH signaling and epithelial–mesenchymal transition. Bioscience Reports, 2021, 41, .	2.4	13
8	A directly GP130â€ŧargeting small molecule ameliorates collagenâ€induced arthritis (CIA) by inhibiting ILâ€6/GP130 signalling and Th17 differentiation. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 628-639.	1.9	7
9	Combination of gp130-targeting and TNF-targeting small molecules in alleviating arthritis through the down-regulation of Th17 differentiation and osteoclastogenesis. Biochemical and Biophysical Research Communications, 2020, 522, 1030-1036.	2.1	4
10	Long non-coding RNA steroid receptor activator promotes the progression of endometrial cancer via Wnt/ β-catenin signaling pathway. International Journal of Biological Sciences, 2020, 16, 99-115.	6.4	24
11	Long Noncoding RNA E2F4as Promotes Progression and Predicts Patient Prognosis in Human Ovarian Cancer. Cancers, 2020, 12, 3626.	3.7	4
12	E2F8 Induces Cell Proliferation and Invasion through the Epithelial–Mesenchymal Transition and Notch Signaling Pathways in Ovarian Cancer. International Journal of Molecular Sciences, 2020, 21, 5813.	4.1	15
13	Local delivery of cardiac stem cells overexpressing HIF-1α promotes angiogenesis and muscular tissue repair in a hind limb ischemia model. Journal of Controlled Release, 2020, 322, 610-621.	9.9	12
14	E2F8 regulates the proliferation and invasion through epithelial-mesenchymal transition in cervical cancer. International Journal of Biological Sciences, 2020, 16, 320-329.	6.4	20
15	Intra-articular delivery of synovium-resident mesenchymal stem cells via BMP-7-loaded fibrous PLGA scaffolds for cartilage repair. Journal of Controlled Release, 2019, 302, 169-180.	9.9	36
16	Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer. Cancer Research and Treatment, 2019, 51, 1117-1127.	3.0	19
17	MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Biochemical and Biophysical Research Communications, 2018, 497, 513-520.	2.1	34
18	Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. Cancer Research and Treatment, 2018, 50, 956-963.	3.0	19

#	Article	IF	CITATIONS
19	Expression levels of the long noncoding RNA steroid receptor activator promote cell proliferation and invasion and predict patient prognosis in human cervical cancer. Oncology Letters, 2018, 16, 5410-5418.	1.8	8
20	Long non-coding RNA, steroid receptor RNA activator (SRA), induces tumor proliferation and invasion through the NOTCH pathway in cervical cancer cell lines. Oncology Reports, 2017, 38, 3481-3488.	2.6	45
21	Lipo-PGE1 suppresses collagen production in human dermal fibroblasts via the ERK/Ets-1 signaling pathway. PLoS ONE, 2017, 12, e0179614.	2.5	14
22	Dysregulated expression of <i>homeobox</i> family genes may influence survival outcomes of patients with epithelial ovarian cancer: analysis of data from The Cancer Genome Atlas. Oncotarget, 2017, 8, 70579-70585.	1.8	7
23	Upregulation of homeobox gene is correlated with poor survival outcomes in cervical cancer. Oncotarget, 2017, 8, 84396-84402.	1.8	23
24	Long Non-coding RNA HOXA11 Antisense Promotes Cell Proliferation and Invasion and Predicts Patient Prognosis in Serous Ovarian Cancer. Cancer Research and Treatment, 2017, 49, 656-668.	3.0	35
25	A Case of Segmental Vitiligo with Generalized Morphea Stabilized by Antimalarial Medication. Annals of Dermatology, 2016, 28, 249.	0.9	2
26	Anti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines. Yonsei Medical Journal, 2016, 57, 33.	2.2	13
27	The long noncoding RNA <i>HOXA11 antisense</i> induces tumor progression and stemness maintenance in cervical cancer. Oncotarget, 2016, 7, 83001-83016.	1.8	78
28	Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning. International Journal of Gynecological Cancer, 2016, 26, 104-113.	2.5	7
29	Upregulation of long noncoding RNA HOXA11 antisense promotes tumor progression and stemness maintenance of cervical cancer cells. Gynecologic Oncology, 2016, 141, 75.	1.4	2
30	Exploration of Fluid Dynamics in Perioperative Patients Using Bioimpedance Analysis. Journal of Gastrointestinal Surgery, 2016, 20, 1020-1027.	1.7	10
31	Nearâ€infrared lightâ€responsive nanomaterials for cancer theranostics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2016, 8, 23-45.	6.1	115
32	The long non-coding RNA <i>HOTAIR</i> increases tumour growth and invasion in cervical cancer by targeting the Notch pathway. Oncotarget, 2016, 7, 44558-44571.	1.8	108
33	Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue. Oncotarget, 2016, 7, 70524-70534.	1.8	19
34	Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of the p38 MAPK pathway. Biochemical and Biophysical Research Communications, 2015, 459, 379-386.	2.1	66
35	Long non-coding RNA HOTAIR is associated with human cervical cancer progression. International Journal of Oncology, 2015, 46, 521-530.	3.3	186
36	Surgical Outcomes of Robotic Radical Hysterectomy Using Three Robotic Arms versus Conventional Multiport Laparoscopy in Patients with Cervical Cancer. Yonsei Medical Journal, 2014, 55, 1222.	2.2	27

#	Article	IF	CITATIONS
37	Nutritional Risk and Physical Activity on Quality of Life in Patients with Colorectal Cancer. Asian Oncology Nursing, 2014, 14, 66.	0.6	8
38	Downregulation of erythroid differentiation regulator 1 as a novel marker of skin tumors. International Journal of Dermatology, 2014, 53, 723-730.	1.0	9
39	Long noncoding RNA HOTAIR is associated with human cervical cancer progression. Gynecologic Oncology, 2014, 133, 5.	1.4	5
40	Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3. Cancer Research and Treatment, 2014, 46, 81-92.	3.0	24
41	Celecoxib and paclitaxel synergistically induce apoptosis in the human ovarian cancer cell line OVCAR-3. Gynecologic Oncology, 2013, 130, e126.	1.4	1
42	Photodynamic therapy-mediated DC immunotherapy is highly effective for the inhibition of established solid tumors. Cancer Letters, 2012, 324, 58-65.	7.2	42
43	LL-37 suppresses sodium nitroprusside-induced apoptosis of systemic sclerosis dermal fibroblasts. Experimental Dermatology, 2011, 20, 843-845.	2.9	24
44	Erythroid differentiation regulator 1 (Erdr1) is a proapototic factor in human keratinocytes. Experimental Dermatology, 2011, 20, 920-925.	2.9	26
45	Erythroid Differentiation Regulator 1, an Interleukin 18-Regulated Gene, Acts as a Metastasis Suppressor in Melanoma. Journal of Investigative Dermatology, 2011, 131, 2096-2104.	0.7	33
46	Response to "Interleukin-18: Friend or Foe for Systemic Sclerosis?― Journal of Investigative Dermatology, 2011, 131, 2496-2497.	0.7	0
47	Vitamin C attenuates ERK signalling to inhibit the regulation of collagen production by LLâ€37 in human dermal fibroblasts. Experimental Dermatology, 2010, 19, e258-64.	2.9	36
48	The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. British Journal of Dermatology, 2010, 163, 959-967.	1.5	28
49	IL-18 Downregulates Collagen Production in Human Dermal Fibroblasts via the ERK Pathway. Journal of Investigative Dermatology, 2010, 130, 706-715.	0.7	47
50	N,N′-Bis(5-aminosalicyl)-L-Cystine is a Potential Colon-specific 5-aminosalicylic Acid Prodrug with Dual Therapeutic Effects in Experimental Colitis. Journal of Pharmaceutical Sciences, 2009, 98, 159-168.	3.3	8
51	Comparison of a 1,550 nm Erbium:Class fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: A simultaneous splitâ€face trial. Lasers in Surgery and Medicine, 2009, 41, 545-549.	2.1	61
52	Collagen Synthesis Is Suppressed in Dermal Fibroblasts by the Human Antimicrobial Peptide LL-37. Journal of Investigative Dermatology, 2009, 129, 843-850.	0.7	67
53	Synthesis and Properties of <i>N</i> , <i>N</i> ′-Bis(5-Aminosalicyl)- <i>L</i> -Cystine as a Colon-Specific Deliverer of 5-Aminosalicylic Acid and Cystine. Drug Delivery, 2008, 15, 37-42.	5.7	10
54	Adrenocorticotropin Hormone Stimulates Interleukin-18 Expression in Human HaCaT Keratinocytes. Journal of Investigative Dermatology, 2007, 127, 1210-1216.	0.7	31

#	Article	IF	CITATIONS
55	Expression of the corticotropin-releasing hormone?proopiomelanocortin axis in the various clinical types of psoriasis. Experimental Dermatology, 2007, 16, 104-109.	2.9	50
56	lmmunoreactivity of corticotropin-releasing hormone, adrenocorticotropic hormone andα-melanocyte-stimulating hormone in alopecia areata. Experimental Dermatology, 2006, 15, 515-522.	2.9	0
57	lmmunoreactivity of corticotropin-releasing hormone, adrenocorticotropic hormone and <i>α</i> -melanocyte-stimulating hormone in alopecia areata. Experimental Dermatology, 2006, 15, 515-522.	2.9	0
58	lmmunoreactivity of corticotropinâ€releasing hormone, adrenocorticotropic hormone and <i>α</i> â€melanocyteâ€stimulating hormone in alopecia areata. Experimental Dermatology, 2006, 15, 515-522.	2.9	38
59	lmmunoreactivity of corticotropin-releasing hormone, adrenocorticotropic hormone and <i>α</i> -melanocyte-stimulating hormone in alopecia areata. Experimental Dermatology, 2006, 15, 515-522.	2.9	0
60	lmmunoreactivity of corticotropin-releasing hormone, adrenocorticotropic hormone andα-melanocyte-stimulating hormone in alopecia areata. Experimental Dermatology, 2006, 15, 515-522.	2.9	47
61	UVB-induced interleukin-18 production is downregulated by tannic acids in human HaCaT keratinocytes. Experimental Dermatology, 2006, 15, 589-595.	2.9	18
62	Investigation of the corticotropin-releasing hormone-proopiomelanocortin axis in various skin tumours. British Journal of Dermatology, 2006, 155, 910-915.	1.5	24
63	A Molecular Mechanism for the Anti-Inflammatory Effect of Taurine-Conjugated 5-Aminosalicylic Acid in Inflamed Colon. Molecular Pharmacology, 2006, 69, 1405-1412.	2.3	43
64	Corticotropin-Releasing Hormone (CRH) Downregulates Interleukin-18 Expression in Human HaCaT Keratinocytes by Activation of p38 Mitogen-Activated Protein Kinase (MAPK) Pathway. Journal of Investigative Dermatology, 2005, 124, 751-755.	0.7	54
65	Metabolic and Pharmacological Properties of Rutin, a Dietary Quercetin Glycoside, for Treatment of Inflammatory Bowel Disease. Pharmaceutical Research, 2005, 22, 1499-1509.	3.5	138
66	Fluoxetine inhibits ATP-induced [Ca] increase in PC12 cells by inhibiting both extracellular Ca influx and Ca release from intracellular stores. Neuropharmacology, 2005, 49, 265-274.	4.1	22
67	Immunohistochemical characterization of cutaneous drug eruptions by STI571. Journal of Dermatological Science, 2005, 38, 9-15.	1.9	13
68	Promoter -202 <i>A/C</i> Polymorphism of Insulin-like Growth Factor Binding Protein-3 Gene and Non-small Cell Lung Cancer Risk. Tuberculosis and Respiratory Diseases, 2005, 58, 359.	1.8	0
69	Epigallocatechin-3-gallate increases intracellular [Ca 2+] in U87 cells mainly by influx of extracellular Ca 2+ and partly by release of intracellular stores. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 260-267.	3.0	27
70	In Vitro Effects of Ciprofloxacin and Roxithromycin on Apoptosis of Jurkat T Lymphocytes. Antimicrobial Agents and Chemotherapy, 2003, 47, 1161-1164.	3.2	43
71	Multiplex PCR for the Detection of Genes Encoding Aminoglycoside Modifying Enzymes and Methicillin Resistance among Staphylococcus Species. Journal of Korean Medical Science, 2003, 18, 631. 	2.5	111
72	Clinical Experience for Sentinel Lymphadenectomy Alone in Early Breast Cancer. Journal of Korean Breast Cancer Society, 2003, 6, 263.	0.1	3

#	Article	IF	CITATIONS
73	Expression of cyclins in ductal hyperplasia, atypical ductal hyperplasia and ductal carcinoma <i>in situ</i> of the breast. Yonsei Medical Journal, 2000, 41, 345.	2.2	6
74	Lobular carcinoma in situ in sclerosing adenosis. Yonsei Medical Journal, 2000, 41, 293.	2.2	12
75	Sentinel lymph node biopsy using radioactive material in breast cancer patients. Journal of Korean Breast Cancer Society, 2000, 3, 104.	0.1	2
76	Primary carcinoid tumor of the testis: immunohistochemical, ultrastructural and DNA flow cytometric study of two cases. Journal of Korean Medical Science, 1999, 14, 57.	2.5	14
77	Solitary fibrous tumor of the orbit, a poorly-recognized orbital lesion. Acta Ophthalmologica, 1999, 77, 704-708.	0.3	40
78	Postoperative autotransfusion using a blood drainage and transfusion device, ConstaVac, in patients with total knee replacement. Daehan Macwi'gwa Haghoeji, 1994, 27, 396.	0.2	0
79	The Influence of the Second Gas Effect on the Alveolar Concentration of the Inhalational Anesthetics that have the Different Solubility. Daehan Macwi'gwa Haghoeji, 1994, 27, 1568.	0.2	0